688137 Novoprotein Scientific Inc.
- 35.58
- -0.34-0.95%
Novoprotein Scientific Inc. News
Express News | Science and Technology Innovation Board Review: The pharmaceutical sector is active throughout the day, and aerospace concept stocks have declined
The synthetic biology concept bottomed out and Ruifeng Hi-Tech rose by more than 15%. Previously, Blue Biotech went out of the 6-game market, with Yiqiao Shenzhou, Offshore Protein, Xinghu Technology, and Lukang Pharmaceutical leading the way in gains.
The synthetic biology concept bottomed out and Ruifeng Hi-Tech rose by more than 15%. Previously, Blue Biotech went out of the 6-game market, with Yiqiao Shenzhou, Offshore Protein, Xinghu Technology, and Lukang Pharmaceutical leading the way in gains.
Private Companies Among Novoprotein Scientific Inc.'s (SHSE:688137) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 17% Last Week
Key Insights Significant control over Novoprotein Scientific by private companies implies that the general public has more power to influence management and governance-related decisions The top 2 sh
Express News | Science and Technology Innovation Board Evaluation: The biological products sector is strong and surging, and the semiconductor and lithium battery sectors are rising
Express News | Science and Technology Innovation Board Evaluation: Low-altitude economy, semiconductor sector falls across the board, biological products sector rises
Near Shore Protein (688137.SH) reported 2023 results, net profit of RMB 12.8436 million, a year-on-year decrease of 85.84%
Near Shore Protein (688137.SH) released its 2023 annual report, achieving operating revenue of 153 million yuan, with...
Near Shore Protein (688137.SH) performance report: 2023 net profit of 12.582 million yuan decreased by 85.79% year on year
On February 23, Ge Longhui (688137.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 153.3318 million yuan, a year-on-year decrease of 42.04%; realized net profit attributable to owners of the parent company of 12.8502 million yuan, a year-on-year decrease of 85.79%; realized net profit attributable to the owners of the parent company after deducting non-recurring gains and losses - 7.082,700 yuan, a year-on-year decrease of 109.13%. At the end of the reporting period, the company's total assets were RMB 230,955,800, down 1.47% from the initial data; owned by the parent company
Near shore protein (688137.SH): 2023 net profit pre-reduced by 86.18% to 84.52%
On January 30, Ge Longhui (688137.SH) announced the 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve operating income of 145 million yuan to 154 million yuan in 2023, a decrease of 119.55 million yuan to 110.55 million yuan over the same period last year, a year-on-year decrease of 45.19% to 41.79%. The company expects net profit attributable to shareholders of listed companies in 2023 to be 12.5 million yuan to 14 million yuan, a decrease of 77.92 million yuan to 76.42 million yuan from the same period last year, and a year-on-year decrease of 86.18% to 84
Private Companies Are Novoprotein Scientific Inc.'s (SHSE:688137) Biggest Owners and Were Hit After Market Cap Dropped CN¥358m
Key Insights The considerable ownership by private companies in Novoprotein Scientific indicates that they collectively have a greater say in management and business strategy 58% of the business is
[BT Financial Report Momentary Analysis] Near Shore Protein 2023 Quarterly Report: Exploring Transformation Under Significant Growth in R&D Investment and Performance Pressure
As an important upstream supplier in healthcare and life sciences, nearshore protein (stock code: 688137) focuses on R&D, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents. The full-process application solutions provided by the company cover various fields such as biopharmaceuticals, in vitro diagnosis, mRNA vaccine drugs, and basic life science research, and serve customers around the world with advanced technology and products with high market recognition. According to the 2023 three-quarter report, the total assets of nearshore protein declined, from 2,338 billion yuan at the end of the previous year to 2,301 billion yuan, showing 1.60%
Coastal Protein (688137.SH): The ban on 2.38 million restricted shares was lifted on December 25
Glonghui announced on December 13|Coastal Protein (688137.SH) announced that the total number of shares in circulation in the company's current stock listing is 2.38 million shares. The stock listing and circulation date is December 25, 2023.
The recombinant collagen concept is active in Jiangsu Wuzhong 4 days 3 board
Gelonghui November 1 | Jiangsu Wu Zhong, Jiangsu, 3 boards in 4 days. Coastal protein once rose 10%, and Shirjia and Opumai followed suit. According to the news, according to Frost & Sullivan's data forecast, by 2026, the market share of collagen-based skin care products will surpass hyaluronic acid, with a compound annual growth rate of 52.6%; by 2027, the overall market size of collagen in China will reach 173.8 billion yuan, of which the market size of non-animal collagen products is 108.3 billion yuan, accounting for 62.3%.
Net profit of 15.88 million yuan for the first three quarters of the release of nearshore protein (688137.SH) fell 82.38% year on year
Coastal Protein (688137.SH) disclosed its report for the third quarter of 2023. The company achieved operating income during the reporting period...
10.12 million restricted shares of nearshore protein (688137.SH) will be listed for circulation on October 9
Onshore Protein (688137.SH) announced that the number of restricted shares currently listed in the company's initial public offering is 10...
Offshore Protein (688137): Regular business resumes growth and consolidates customer base
Incident description The company released its 2023 annual report. 2023Q2 In a single quarter, the company achieved operating income of 32 million yuan, a year-on-year decrease of 59.63%; net profit for the return mother was 1,219,600 yuan, a year-on-year decrease of 96.11%
The semi-annual net profit of nearshore protein (688137.SH) was 12.363,300 yuan, a year-on-year decrease of 82.66%
GLONGHUI, August 28 | Offshore Protein (688137.SH) disclosed the 2023 semi-annual report, achieving operating income of 74.6892 million yuan, down 55.10% year on year; net profit attributable to shareholders of listed companies was 123.63 million yuan, down 82.66% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 236,400 yuan, with a profit of 69.2011 million yuan for the same period last year; basic earnings per share of 0.18 yuan.
Novoprotein Scientific Inc. (SHSE:688137) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
It is hard to get excited after looking at Novoprotein Scientific's (SHSE:688137) recent performance, when its stock has declined 11% over the past three months. But if you pay close attention, you
CRO concept stocks continue to rise, Keyuan Pharmaceutical continues to rise two times in a row
On August 9, GLONGHUI | Keyuan Pharmaceuticals sold two times in a row. C Jinkai rose more than 19%. Nankai Protein, Shengnuo Biotech, and Novo Biotech registered the highest gains, while Tiger Pharmaceuticals, Medici, and Hongbo Pharmaceuticals followed suit.
The registration date for Inshore Protein (688137.SH) to distribute shares of 0.5 yuan per share in 2022 is June 28
According to the Zhitong Finance App, Offshore Protein (688137.SH) announced that the company will implement the 2022 annual equity distribution, with a cash dividend of 0.5 yuan (tax included) per share. The equity registration date is June 28.
“Oolong” was reported and criticized for the offshore protein annual report falling by more than 70% in net profit in the first quarter
“Investor Network” Zhang Wei's disclosure of the annual report of the listed company should have been a meticulous and rigorous job. However, there are also some “newcomers” listed. The company was criticized by regulators because the relevant personnel were negligent in their work and the annual reports prepared were full of loopholes. On April 27, part of the 2022 annual report submitted by the Science and Technology Innovation Board company Inshore Protein (688137.SH) was incomplete and inaccurate, and there were major omissions in the preparation of the annual report. On June 2, the Shanghai Stock Exchange issued a disciplinary decision (hereinafter referred to as the “Decision”), informing and criticizing Inshore Protein and its director Wang Duqiang. In terms of performance, nearshore protein's revenue and net profit in 2022
Analysis
Price Target
No Data
